• Dihydrotestosterone: Applied Research Workflows

  2026-09-14

  Dihydrotestosterone (DHT) provides a defined androgen receptor stimulus for studying EGFR–ERBB2 signaling in bladder cancer, androgen-responsive prostate assays, and neuromuscular disease models. This workflow-focused guide connects concentration-controlled cell experiments with translational readouts while emphasizing formulation, controls, and interpretation limits.

• SAG Workflow Guide for Hedgehog Pathway Studies

  2026-09-14

  Build more reproducible Hedgehog pathway experiments with SAG, from reporter assays and mitochondrial rescue studies to sex-aware demyelination models. This guide separates validated use cases from exploratory applications and provides practical dosing, formulation, and troubleshooting strategies.

• Abiraterone Acetate in 3D Prostate Models

  2026-09-13

  Abiraterone acetate is a CYP17 inhibitor with a distinctive value in prostate cancer research: it can test whether a patient-derived 3D spheroid retains a therapeutically actionable androgen biosynthesis phenotype. This guide connects compound chemistry, assay design, and interpretation of apparently negative responses.

• Lapatinib (GW572016) Research Workflow

  2026-09-12

  Lapatinib, also known as GW572016, supports receptor-defined EGFR and HER2 kinase studies as well as phenotype-first assays of proliferation, invasion, and angiogenesis. This workflow separates direct target engagement from downstream biology, helping researchers interpret results in HER2-high and HER2-low models without overstating mechanism.

• Poria Cocos Polysaccharides Target NRF2-Ferroptosis

  2026-09-11

  The reference study identifies a mechanistic connection between Poria cocos polysaccharides, NRF2 regulation, and ferroptosis in alcoholic liver disease. Using rat and alcohol-injured cell models, it shows that PCP improves biochemical and inflammatory injury markers while reducing oxidative and iron-associated damage, providing a framework for studying NRF2-dependent hepatoprotection.

• Plant Autophagy: Condensates-to-VAPVs Pathway

  2026-09-11

  Jiang et al. identify a plant-specific condensates-to-VAPVs conversion pathway that directs autophagosomes toward vacuolar degradation. The study links VPS41 organization, ARLA1 GTPases, SNARE coupling, autophagic flux, and plant survival, while showing that Arabidopsis autophagy is largely independent of the canonical RAB7 route.

• Patient-Derived Gastric Cancer Assembloids

  2026-09-10

  This 2025 study introduces patient-matched gastric cancer assembloids that combine tumor organoids with tumor-derived stromal subpopulations. The model captures stromal effects on gene expression and drug response, creating a more physiologically relevant platform for studying resistance and personalized treatment strategies.

• Erlotinib (NSC 718781): EGFR Research Guide

  2026-09-10

  Erlotinib (NSC 718781) is an orally bioavailable, reversible EGFR tyrosine kinase inhibitor with nanomolar biochemical and cellular potency. This guide connects EGFR pathway inhibition with reproducible assay design and clarifies why emerging SCUBE3 biology does not yet establish an erlotinib-specific mechanism.

• A40926: From Biosynthesis to Assay Design

  2026-09-09

  A40926 is a dalbavancin precursor whose biosynthetic regulation directly informs reproducible antibacterial research. This guide connects engineered fermentation, mechanism-based assay design, MIC interpretation, and translational limitations in one evidence-grounded framework.

• Halazone: From Water Disinfection to Ion-Channel Insight

  2026-09-09

  Halazone is more than a conventional water disinfection agent: its HOCl-generating chemistry supports rapid bactericidal workflows, while comparative nerve-fiber experiments reveal how oxidative modification can reshape sodium-current inactivation. This article connects those domains without overstating the evidence, offering translational researchers a practical framework for assay design, product selection, and future antimicrobial resistance research.

• Perospirone Assay Design: Receptor to Kv1.5

  2026-09-08

  Perospirone and SM-9018 free base provide a powerful paired model for studying receptor pharmacology alongside vascular ion-channel effects. This article presents an evidence-led assay strategy that connects schizophrenia research with carefully bounded cardiovascular investigation.

• IPR-803 and uPAR–uPA Inhibition in Metastasis

  2026-09-08

  The reference study established compound 4, identified here as IPR-803, as a chemically tractable inhibitor of the urokinase receptor–urokinase-type plasminogen activator interaction. By combining synthesis, orthogonal binding assays, invasion studies, pharmacokinetics, and a breast cancer metastasis model, the authors connected direct uPAR engagement with reduced tumor-cell invasion and lung metastatic burden.

• Deep Learning and iPSC-CMs for Cardiotoxicity

  2026-09-07

  Grafton et al. developed a high-content screening workflow that combines human iPSC-derived cardiomyocytes with deep-learning image analysis to identify cardiotoxic phenotypes early in discovery. The study shows how a compact, phenotype-based score can prioritize compounds with diverse mechanisms while also highlighting important limits on translating cellular signals into clinical cardiac risk.

• MOB1A/B Loss Rewires Intestinal Signaling

  2026-09-07

  Bae et al. show that intestinal epithelial MOB1A/B depletion produces an unusual combination of early epithelial hyperproliferation, Wnt suppression, stem-cell loss, and BMP/TGF-β activation. Pharmacological pathway inhibition partially restores secretory-cell differentiation but not intestinal stem-cell pools, positioning MOB1A/B as an important coordinator of epithelial homeostasis.

• Phosbind Acrylamide for Protein Phosphorylation

  2026-09-05

  Phosbind Acrylamide enables antibody-independent separation of phosphorylated and non-phosphorylated proteins during SDS-PAGE. This workflow connects practical phosphorylation-state analysis with the CLK4–NEXN mechanism implicated in pathological cardiac hypertrophy.

7872 records 1/525 page Next 12345 下5页 Last page